2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. 17β-HSD

17β-HSD

17beta-HSD; 17β-hydroxysteroid dehydrogenases; 17 beta-hydroxysteroid dehydrogenase

 

17β-HSD Related Products (107):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-157724
    HSD17B13-IN-76
    		Inhibitor
    HSD17B13-IN-76 (Compound 773) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-76 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-76
  • HY-157723
    HSD17B13-IN-74
    		Inhibitor
    HSD17B13-IN-74 (Compound 760) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-74 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-74
  • HY-162213
    HSD17B13-IN-86
    		Inhibitor
    HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-86
  • HY-161211
    HSD17B13-IN-7
    		Inhibitor
    HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC50s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research.
    HSD17B13-IN-7
  • HY-163251
    HSD17B13-IN-52
    		Inhibitor
    HSD17B13-IN-52 (Compound 84) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-52 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-52
  • HY-118382
    SCH-451659
    		Inhibitor
    SCH-451659 is an inhibitor of 17β-hydroxysteroid dehydrogenases (17β-HSDs) for cancer research.
    SCH-451659
  • HY-163259
    HSD17B13-IN-62
    		Inhibitor
    HSD17B13-IN-62 (141) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-62
  • HY-161218
    HSD17B13-IN-17
    		Inhibitor
    HSD17B13-IN-17 (compound 9) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-17? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
    HSD17B13-IN-17
  • HY-163261
    HSD17B13-IN-66
    		Inhibitor
    HSD17B13-IN-66 (Compound 146) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-66 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-66
  • HY-162210
    HSD17B13-IN-65
    		Inhibitor
    HSD17B13-IN-65 (Compound 168) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-65 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-65
  • HY-161223
    HSD17B13-IN-27
    		Inhibitor
    HSD17B13-IN-27 (compound 30) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and ?＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-27? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
    HSD17B13-IN-27
  • HY-157632
    HSD17B13-IN-13
    		Inhibitor
    HSD17B13-IN-13 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-13 can be used in the research of liver diseases, such as NAFLD.
    HSD17B13-IN-13
  • HY-161220
    HSD17B13-IN-19
    		Inhibitor
    HSD17B13-IN-19 (compound 16) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-19? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
    HSD17B13-IN-19
  • HY-163263S
    HSD17B13-IN-80-dsub>3
    		Inhibitor
    HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-80-dsub>3</sub>
  • HY-161230
    HSD17B13-IN-75
    		Inhibitor
    HSD17B13-IN-75 (Compound 21) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-75 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-75
  • HY-157674
    HSD17B13-IN-46
    		Inhibitor
    HSD17B13-IN-46 (Compound 351) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-46 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-46
  • HY-163245
    HSD17B13-IN-32
    		Inhibitor
    HSD17B13-IN-32(Compound 67) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-32can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-32
  • HY-157665
    HSD17B13-IN-39
    		Inhibitor
    HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.
    HSD17B13-IN-39
  • HY-148926
    HSD17B13-IN-1
    		Inhibitor
    HSD17B13-IN-1 (compound 2) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-1? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
    HSD17B13-IN-1
  • HY-161224
    HSD17B13-IN-31
    		Inhibitor
    HSD17B13-IN-31 (compound 32) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC50 of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-31? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis).
    HSD17B13-IN-31